These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8198018)

  • 1. Clinical implications of the biopharmaceutical properties of fluvastatin.
    Deslypere JP
    Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of fluvastatin and specific drug interactions.
    Smith HT; Jokubaitis LA; Troendle AJ; Hwang DS; Robinson WT
    Am J Hypertens; 1993 Nov; 6(11 Pt 2):375S-382S. PubMed ID: 8297546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
    Dujovne CA; Davidson MH
    Am J Med; 1994 Jun; 96(6A):37S-40S. PubMed ID: 8017465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated clinical safety experience with fluvastatin.
    Jokubaitis LA
    Am J Cardiol; 1994 May; 73(14):18D-24D. PubMed ID: 8198019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.
    Sabia H; Prasad P; Smith HT; Stoltz RR; Rothenberg P
    J Cardiovasc Pharmacol; 2001 May; 37(5):502-11. PubMed ID: 11336101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of current clinical findings with fluvastatin.
    Garnett WR
    Am J Cardiol; 1996 Sep; 78(6A):20-5. PubMed ID: 8875971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
    Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
    Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
    Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.
    Tse FL; Jaffe JM; Troendle A
    J Clin Pharmacol; 1992 Jul; 32(7):630-8. PubMed ID: 1640002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
    Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.